IL115966A - Neuroprotective pharmaceutical compositions comprising GDNF - Google Patents

Neuroprotective pharmaceutical compositions comprising GDNF

Info

Publication number
IL115966A
IL115966A IL11596695A IL11596695A IL115966A IL 115966 A IL115966 A IL 115966A IL 11596695 A IL11596695 A IL 11596695A IL 11596695 A IL11596695 A IL 11596695A IL 115966 A IL115966 A IL 115966A
Authority
IL
Israel
Prior art keywords
gdnf
pharmaceutical compositions
present
neuroprotective pharmaceutical
neuroprotective
Prior art date
Application number
IL11596695A
Other languages
English (en)
Other versions
IL115966A0 (en
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Publication of IL115966A0 publication Critical patent/IL115966A0/xx
Publication of IL115966A publication Critical patent/IL115966A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11596695A 1994-11-15 1995-11-12 Neuroprotective pharmaceutical compositions comprising GDNF IL115966A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34082194A 1994-11-15 1994-11-15

Publications (2)

Publication Number Publication Date
IL115966A0 IL115966A0 (en) 1996-01-31
IL115966A true IL115966A (en) 1999-11-30

Family

ID=23335068

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11596695A IL115966A (en) 1994-11-15 1995-11-12 Neuroprotective pharmaceutical compositions comprising GDNF

Country Status (13)

Country Link
US (1) US5733875A (de)
EP (1) EP0792160B1 (de)
JP (1) JPH10508839A (de)
AT (1) ATE205088T1 (de)
AU (1) AU691349B2 (de)
CA (1) CA2204911C (de)
DE (1) DE69522578T2 (de)
DK (1) DK0792160T3 (de)
ES (1) ES2159647T3 (de)
IL (1) IL115966A (de)
PT (1) PT792160E (de)
WO (1) WO1996014861A1 (de)
ZA (1) ZA959714B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
WO1997019693A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
NZ335207A (en) 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
WO2001030375A2 (en) * 1999-10-29 2001-05-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdnf for treating corneal defects
US20040197900A1 (en) * 2003-04-04 2004-10-07 Arnon Rosenthal Foggy
PL2019683T5 (pl) 2006-04-25 2022-12-05 The Regents Of The University Of California Podawanie czynników wzrostu do leczenia zaburzeń OUN
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11912750B2 (en) 2016-11-10 2024-02-27 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
EP3973979A1 (de) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Tight-junction (zonulae occludentes)-protein zur verwendung in der behandlung oder vorbeugung einer neurologischen störung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006116A1 (en) * 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
FR2717824B1 (fr) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
IL115966A0 (en) 1996-01-31
DK0792160T3 (da) 2001-11-19
ES2159647T3 (es) 2001-10-16
AU691349B2 (en) 1998-05-14
DE69522578D1 (de) 2001-10-11
CA2204911A1 (en) 1996-05-23
CA2204911C (en) 2002-07-23
PT792160E (pt) 2002-02-28
ZA959714B (en) 1997-10-15
US5733875A (en) 1998-03-31
ATE205088T1 (de) 2001-09-15
JPH10508839A (ja) 1998-09-02
AU3752895A (en) 1996-06-06
WO1996014861A1 (en) 1996-05-23
EP0792160A1 (de) 1997-09-03
EP0792160B1 (de) 2001-09-05
DE69522578T2 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
IL115966A0 (en) Methods of using gdnf as a neuroprotective agent
HUT68498A (en) L-dopa ester compositions and process to prepare them
EP1674107B8 (de) Verwendung von Daptomycin
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
AU3805195A (en) Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast
PL316080A1 (en) Pharmaceutic composition for sublingual or intrabuccal administration
EP0830369A4 (de) Nor-pregnane zur induzierung hypothalamischer effekte
AU4778893A (en) System of drug delivery to the lymphatic tissues
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
IL108865A (en) Azabicyclic compounds their preparation and pharmaceutical compositions comprising them
GB9212308D0 (en) Therapeutic compositions
GB2305606B (en) Drug delivery composition for the nasal administration of ICAM-1
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
AU4633893A (en) Liposomal formulations for administering to cancer patients
DK0585314T3 (de)
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
MX9702253A (es) Nuevos estrenos para inducir efectos hipotalamicos
BG101929A (en) Benzamides for neurodegenerative disorder treatment
AU7076494A (en) Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of parkinson disease
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
CA2064112A1 (en) .alpha.-dihydroergocryptine pharmaceutical preparations with neuroprotective activity

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees